Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan

INTRODUCTION: Gastroesophageal reflux disease is a common condition, and proton pump inhibitors (PPIs) are the mainstays of treatment. However, concerns have been raised about the safety of PPIs. A potassium‐competitive acid blocker (P‐CAB), vonoprazan (VPZ), was recently introduced, which may provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Habu, Yasuki, Hamasaki, Ryuhei, Maruo, Motonobu, Nakagawa, Tatsuya, Aono, Yuki, Hachimine, Daisaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411401/
https://www.ncbi.nlm.nih.gov/pubmed/34484992
http://dx.doi.org/10.1002/jgf2.429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411401/
https://www.ncbi.nlm.nih.gov/pubmed/34484992
http://dx.doi.org/10.1002/jgf2.429

Ejemplares similares